|
|
September 27, 2011
Applied Drug Delivery: Options for Vitamin D Analogs |
Speakers for this event: 
Dr. Hector F. DeLuca, Professor Emeritus, Department of Biochemistry, University of Wisconsin-
Madison 
Julien Meissonnier, Director, Research and Development, Catalent Pharma Solutions |
|
Key Takeaway Points:
- Current and future of oral Vitamin D3 analogs
- Main biopharmaceutical, physico-chemical and industrial hurdles to the development of appropriate drug delivery systems
- Preferred drug delivery systems for Vit D3 analogs
Vitamin D itself is biologically inactive and must be metabolized in the liver to the circulating form, 25-hydroxyvitamin D. This compound is biologically inactive at physiologic concentrations and must be further 1-hydroxylated by the CYP27B1 found largely in the proximal convoluted tubule cells of the kidney.
1a,25-Dihydroxyvitamin D3 (1,25-(OH)2D3) is the final hormonal form that carries out many functions including the elevation of serum calcium and phosphorus that supports mineralization of bone. It carries out this function by increasing intestinal absorption of calcium and phosphate, increasing calcium reabsorption in kidney and the mobilization of calcium from bone.
1a,25-(OH)2D3 is available as capsules, tablets, and in intravenous preparations. Its primary use has been the treatment of renal failure patients to suppress secondary hyperparathyroidism that causes renal osteodystrophy. It is also used for treatment of osteoporosis and vitamin D-resistant conditions.
1,25-(OH)2D3 acts through a single vitamin D receptor found in the nucleus of target cells. Current views of this mechanism will be presented. There have been many postulated functions of vitamin D signaling possible new uses for 1,25-(OH)2D3 and its analogs. Autoimmune disease, colorectal, prostate, and breast cancers are current possible targets for therapy. Furthermore, analogs have largely replaced 1,25-(OH)2D3 in the treatment of renal failure patients. New and more selective analogs are under development that show promise as therapeutic agents.
|
| THIS PROGRAM IS INTENDED FOR: |
- Chief Scientific Officers
- Vice Presidents, Directors of Research & Development
- Drug Development Scientists
- Process Development Scientists
- Process Engineer Development Scientists
- Directors, Managers of Technical Development, Upstream Development, Technology Assessment
From pharmaceutical companies working in product development of all dosage forms
|
|
|
Hector F. DeLuca, Professor Emeritus, Department of Biochemistry, University of Wisconsin-Madison
Dr. Hector DeLuca earned a BA in chemistry (with honors) from the University of Colorado in 1951, and a PhD in biochemistry from the University of Wisconsin-Madison in 1955 with Dr. Harry Steenbock, a pioneer in vitamin D research. In 1959, Dr. DeLuca joined the Biochemistry Department at the University of Wisconsin as an Assistant Professor, and in 1965-2011, he was promoted to full Professorship (Harry Steenbock Research Professor); 6/2011 became Professor Emeritus of Biochemistry. From 1970-1986 and from 1991-2005, he was also the Chairman of the Department of Biochemistry.
Dr. DeLuca has devoted his research career mainly to vitamin D and physiological events linked to the function of this vitamin. His major initial discoveries were the identification of the vitamin D active forms, 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3, and the characterization of the enzymes involved in the vitamin D metabolic pathways. His group essentially defined the vitamin D-based endocrine system. Dr. DeLuca’s continuing research has made major contributions to various important aspects of vitamin D physiology, metabolism and function, including cloning the vitamin D receptor, identifying and characterizing the CYP24A1 that degrades the active forms of vitamin D, and elucidating the mechanisms of the regulation of genes by 1,25-dihydroxyvitamin D3. Among the most important research activities in Dr. DeLuca’s laboratory has been the synthesis of tissue-specific analogs of vitamin D for the treatment of diseases. His group has produced eight pharmaceuticals that are used for the treatment of diseases, including osteoporosis, vitamin D-resistant rickets, and bone diseases linked to kidney failure.
Dr. DeLuca has received numerous local and international awards and honors. He was elected to the membership of the U.S. National Academy of Sciences and the American Academy of Sciences in 1979. He is a member of a number of scientific societies. He has over 1,150 publications in the fields of vitamin D, calcitonin, parathyroid hormone and vitamin A; he has over 205 active US patents plus over 722 foreign filings corresponding to the U.S. patents. |
 |
Julien Meissonnier, Director, Research and Development, Catalent Pharma Solutions
With 13 years of experience in pharmaceutical development, Mr. Meissonnier leads Catalent’s European centre of excellence for the development of lipid-based drug delivery solutions. He provides technical and scientific leadership for the development of poorly soluble drugs that lead to approvable regulatory dossiers.
Mr. Meissonnier received his Engineer Degree in Physico-Chemistry from the ISMRa in Caen, France. He is an expert in his field and currently sits on the Board of Directors with the Alsace Biovalley life sciences and healthcare cluster based in France. As a board member, he supports Alsace BioValley in its efforts to continue driving growth in the life sciences by identifying and coordinating ambitious projects that will create employment opportunities in the region.
|
| OUR XTALKS PARTNER FOR THIS EVENT: |
|
|
|
Catalyst + Talent. Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. With over 75 years of experience, we have the deepest expertise, the broadest offerings, and the most unique technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results.
Catalent develops. With our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products.
Catalent delivers. As the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and strengthening patient compliance for better treatments.
Catalent supplies. Globally positioned to serve all your manufacturing and commercial packaging needs, we are the largest, most reliable supplier in pharmaceutical outsourcing.
Catalent. More products. Better treatments. Reliably supplied.™ |
| |
|
|
|
|
|
|